Tirzepatide for Reducing HbA1c and Body Weight in Type 2 Diabetes with Juan Frias, MD


Principal investigator of the SURPASS-2 trial discusses the results of the trial and how it informs clinicians on the use of tirzepatide versus currently approved diabetes medications.

What has been hailed by some endocrinologists as a revolutionary agent for type 2 diabetes management is showing promise against a staple in diabetes management in a recent phase 3 trial.

The trial looked at tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, in 5 mg, 10 mg, and 15 mg doses and compared it against 1 mg semaglutide. Topline results of the trial, which were announced in a statement from Eli Lilly on March 4, suggest use of tirzepatide was associated with reductions in HbA1c ranging 2.09-2.46% and body weight from 7.8-12.4 kg, depending on dosage used.

SURPASS-2 was designed as a 40-week, randomized, open-label trial of 1879 adults with type 2 diabetes. The study cohort had a mean weight of 206.6 pounds at baseline and a mean HbA1c level of 8.28%. These patients were randomized in a 1:1:1:1 ratio to either 5 mg, 10 mg, or 15 mg tirzepatide or 1 mg semaglutide.

Upon analysis, the 5, 10, and 15 mg doses of tirzepatide were associated with mean HbA1c reductions of -2.09, -2.37, and -2.46%, respectively, compared to a mean reduction of -1.86% with semaglutide. Mean body weight reductions were -7.8, -10.3, and -12.4 kg with the 5, 10, and 15 mg doses, respectively, compared to -6.2 kg with semaglutide.

When assessing percentage of patients who reached a target HbA1c of 7% or less, investigators found more than 85% of patients receiving any dose of tirzepatide reached 7% compared to 81.1% of those receiving semaglutide. Of note, tirzepatide 15 mg was associated with greatest percentage of patients meeting an HbA1c of 7% at 92.2% of patients.

For more on the results of SURPASS-2 and what it tells us about use of tirzepatide, check out this interview with principal investigator Juan Frias, MD, medical director of the National Research Institute.

Related Videos
Laxmi Mehta, MD | Credit: American Heart Association
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Erin Michos, MD | Credit: Johns Hopkins University
© 2024 MJH Life Sciences

All rights reserved.